From 'Passive Supplementation' to 'Active Repair': Melatonin Reshapes the Treatment Paradigm for Late-Onset Hypogonadism by Targeting Leydig Cell Senescence.
Melatonin targets multiple aging pathways in testicular cells linked to late-life testosterone decline, though clinical testing in men remains sparse.
This Aging Cell review proposes melatonin as a mechanistically novel intervention for late-onset hypogonadism (LOH) by targeting the multiple molecular pathways of Leydig cell senescence (oxidative stress, mitochondrial dysfunction, SASP, epigenetic remodeling). While preclinical data are promising, clinical evidence remains preliminary and the review appropriately frames this as a translational research priority.
What the study was
- Study design
- Narrative review (preclinical + preliminary clinical evidence)
- Population
- Aging men with late-onset hypogonadism
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Aging Cell
Why it surfaced
Aging Cell (reputable) review; melatonin for LOH is novel framing but clinical evidence thin; mainly preclinical focus; limited immediate clinical applicability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.